secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchestra BioMed Holdings, Inc. (OBIO)
CIK:        0001814114
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001104659-26-015315
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Orchestra BioMed increases CEO base salary 4%, President/COO 10%; updates bonus plan and RSU vesting.
--------------------------------------------------------------------------------

- CEO David Hochman base salary raised 4%; target bonus increased from 80% to 100% of base for 2026.
- President/COO Mark Sherman base salary raised 10%; target bonus increased from 80% to 90% of base.
- 2026 bonus plan ties to clinical trial enrollment milestones for BACKBEAT and Virtue SAB studies.
- RSU awards now vest 25% at 18, 24, 30, and 36 months; prior schedule changed.
- CFO Andrew Taylor's bonus can be adjusted -45% to +0% based on individual performance objectives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814114/000110465926015315/0001104659-26-015315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814114/000110465926015315/tm266305d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-015315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer